At Celgene, we believe that a commitment to medical progress achieved through innovative science and life-enhancing new therapies must go hand in hand with a corresponding promise to ensure that patients who can benefit from our discoveries have the opportunity to do so.
Our vision as a company is to build a major global biopharmaceutical corporation while focusing on the discovery, the development, and the commercialisation of products for the treatment of cancer and other severe, immune, inflammatory conditions.
There are numerous clinical trials taking place at major medical centres in the UK, Europe and around the world using compounds from Celgene. Marketed therapies and investigational compounds include those for incurable haematological cancers and solid tumours as well as immune-inflammatory related diseases including; multiple myeloma (MM), myelodysplastic syndromes (MDS), chronic lymphocytic leukaemia (CLL), chronic myelomonocytic leukaemia (CMML), mantle cell lymphoma (MCL), acute myeloid leukaemia (AML), non-Hodgkin’s lymphoma (NHL), pancreatic cancer, breast cancer, non-small lung cancer, melanoma, psoriasis, psoriatic arthritis and Crohn’s disease.
Date of preparation: May 2015